Orchid gets MHPRA approval for API

Orchid Chemicals & Pharmaceuticals' has received Medicines and Healthcare products Regulatory Agency (MHRA) approval for its Betalactam Active Pharmaceutical Ingredient (API) facility at Aurangabad, near Mumbai.

CHENNAI: Orchid Chemicals & Pharmaceuticals' has received Medicines and Healthcare products Regulatory Agency (MHRA) approval for its Betalactam Active Pharmaceutical Ingredient (API) facility at Aurangabad, near Mumbai.

This important regulatory approval received for this state-of-the-art manufacturing facility at Aurangabad is a major milestone for Orchid on several counts, Orchid managing director K Raghavendra Rao said here on Monday.

The MHRA approval is an important step in the overall regulatory road map for and marketing of the Orchid's key betalactam product, Piperacillin - Tazobactam in the lucrative European markets.

It also signifies the first major international approval for the Aurangabad API manufacturing complex, which is slated to play a major role in diversification of the Orchid's product range in terms of niche, premium antibiotics and other pharmaceutical products, he added.

The company would be formulating Piperacillin - Tazobactam in its state-of-the-art dosage form plant at Irungattukottai, Chennai, which is also under the inspection processes. This product is part of the distribution arrangements with two reputed generic partners for the regulated markets of US and Europe.
READ MORE
ADVERTISEMENT

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › Orchid gets MHPRA approval for API
Text Size:AAA
Success
This article has been saved

*

+